IRIS
BUCCISANO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 48.610
EU - Europa 6.515
AS - Asia 6.425
SA - Sud America 1.004
AF - Africa 127
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 16
Totale 62.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.403
SG - Singapore 2.843
IT - Italia 1.461
CN - Cina 1.434
DE - Germania 1.345
RU - Federazione Russa 893
BR - Brasile 795
UA - Ucraina 628
HK - Hong Kong 591
IE - Irlanda 542
VN - Vietnam 515
GB - Regno Unito 398
FR - Francia 361
KR - Corea 236
FI - Finlandia 209
JP - Giappone 192
SE - Svezia 171
IN - India 147
NL - Olanda 134
CA - Canada 123
PL - Polonia 95
AR - Argentina 71
AT - Austria 59
ID - Indonesia 57
MX - Messico 55
BD - Bangladesh 51
ES - Italia 47
IQ - Iraq 47
TR - Turchia 45
ZA - Sudafrica 42
AU - Australia 37
PH - Filippine 36
BE - Belgio 32
EG - Egitto 31
PK - Pakistan 30
IR - Iran 28
EC - Ecuador 27
PE - Perù 24
UZ - Uzbekistan 23
CO - Colombia 21
SA - Arabia Saudita 21
CL - Cile 20
CZ - Repubblica Ceca 20
VE - Venezuela 20
MY - Malesia 18
TH - Thailandia 18
PY - Paraguay 16
CH - Svizzera 14
TW - Taiwan 14
LT - Lituania 12
MA - Marocco 12
IL - Israele 11
RO - Romania 11
AE - Emirati Arabi Uniti 10
GR - Grecia 10
EU - Europa 9
KE - Kenya 9
PT - Portogallo 9
TN - Tunisia 9
AL - Albania 8
HR - Croazia 8
NP - Nepal 8
RS - Serbia 8
DO - Repubblica Dominicana 7
JO - Giordania 7
CR - Costa Rica 6
KG - Kirghizistan 6
DZ - Algeria 5
HU - Ungheria 5
LB - Libano 5
PS - Palestinian Territory 5
UY - Uruguay 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BO - Bolivia 4
DK - Danimarca 4
KZ - Kazakistan 4
NG - Nigeria 4
NO - Norvegia 4
QA - Qatar 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BH - Bahrain 3
BY - Bielorussia 3
EE - Estonia 3
GT - Guatemala 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
CY - Cipro 2
ET - Etiopia 2
GA - Gabon 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
Totale 62.710
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.566
Wilmington 11.985
Houston 9.194
Singapore 1.577
Fairfield 1.533
Ashburn 1.212
Ann Arbor 1.086
Chandler 1.080
San Jose 815
Seattle 663
Hong Kong 569
Beijing 551
Jacksonville 538
Cambridge 531
Dublin 486
New York 444
Rome 443
Dearborn 384
Medford 352
Santa Clara 267
The Dalles 257
Dallas 253
Los Angeles 221
Ho Chi Minh City 181
Council Bluffs 166
Lawrence 164
Tokyo 163
Zhengzhou 152
Lauterbourg 122
Milan 120
Moscow 118
Boardman 102
Buffalo 99
Hanoi 95
San Diego 83
São Paulo 77
Munich 75
London 65
Orem 64
Menlo Park 60
Mülheim 59
Brooklyn 58
Helsinki 55
Creede 54
Shanghai 53
Warsaw 50
Chicago 48
Redwood City 46
Bologna 45
Engelhard 44
Nanjing 40
North Bergen 39
Jakarta 38
Montreal 37
Nuremberg 37
Toronto 36
Frankfurt am Main 35
Hefei 34
Redondo Beach 34
Atlanta 32
Da Nang 30
Phoenix 30
Guangzhou 29
Norwalk 29
Stockholm 29
Chennai 28
Denver 28
Brussels 27
Johannesburg 27
Kraków 27
Kunming 26
Center 25
Seoul 25
Amsterdam 24
Rio de Janeiro 24
San Francisco 24
University Park 24
Hangzhou 23
Verona 23
Falls Church 22
Columbus 21
Palo Alto 21
Florence 20
Paris 20
Wuhan 20
Mexico City 19
Vienna 19
Baghdad 18
Lappeenranta 18
Manchester 18
Naples 18
Boston 17
Haiphong 17
Lima 17
Porto Alegre 17
Mountain View 16
Pune 16
Turku 16
Ankara 15
Belo Horizonte 15
Totale 51.669
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 661
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 627
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 542
CD7 expression in acute myeloid leukemia 529
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 516
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 512
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 506
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 504
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 504
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 497
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 496
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 494
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 493
An unusual endoscopic finding in a patient with melena: Multiple gastric ulcers of regular shape 491
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 489
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 482
Clinical significance of CD38 expression in chronic lymphocytic leukemia 476
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 475
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 474
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 472
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 470
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 470
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 470
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 469
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 469
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 465
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 463
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 461
Cord blood transplantation in adults with acute myeloid leukaemia. 461
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 461
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 460
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 460
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 460
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 460
Biological features of acute myeloid leukemia in the elderly 460
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 459
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 452
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 448
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 445
AML-M0: a biological and clinical profile 445
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 442
Biological pattern of AML-M0 versus AML-M1: Response 440
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 439
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 438
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 438
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 436
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 434
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 432
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 430
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 430
Blood stem cell processing 427
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 427
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 427
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 425
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 423
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 422
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 421
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 419
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 418
Outcomes of allogeneic stem cell transplantation for secondary therapy-related acute myeloid leukaemia 418
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study 416
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 416
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 416
P-glycoprotein expression in de novo acute myeloid leukemia 416
Azacitidine for the treatment of patients with acute myeloid leukemia 414
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 413
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 411
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 411
2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party 408
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 404
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 404
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 403
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 401
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 401
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 399
Monitoring of minimal residual disease in acute myeloid leukemia 398
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 397
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors 397
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 397
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 396
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 395
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 394
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 394
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 393
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 392
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 391
Treatment of low-blast count AML using hypomethylating agents 390
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 388
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 388
Reversible hyporegenerative anemia during natalizumab treatment 388
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 387
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 387
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. 385
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 384
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 384
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 382
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 378
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission? 376
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 373
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 369
Totale 43.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 153.016
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 153.016
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021428 0 0 0 0 0 0 0 0 0 0 328 100
2021/20221.970 66 193 81 67 54 194 131 129 167 177 136 575
2022/20232.902 285 232 218 295 198 569 318 188 331 51 161 56
2023/20241.651 137 48 197 48 136 500 78 112 40 47 43 265
2024/20254.722 171 973 518 277 110 318 318 251 496 457 400 433
2025/20268.304 862 418 1.099 719 848 394 998 1.049 1.060 841 16 0
Totale 63.509